Revenue
2016
2019
2020
2021
2022
2023
2024
2025
Cartesian Therapeutics, Inc. (RNAC)
Price—Loading quote
Net income
2016
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $400,000 | $38.3M | $26.0M | $110.8M | $85.1M | $16.6M | $6.7M | $8.1M | $6.0M | $3.0M |
| Research & development | $58.0M | $45.1M | $71.3M | $72.4M | $68.7M | $54.5M | $42.7M | $29.7M | $23.0M | $10.5M |
| Operating expenses | $146.2M | $82.8M | $112.4M | $96.2M | $89.7M | $73.4M | $59.1M | $42.8M | $31.3M | $18.4M |
| Operating income | −$143.4M | −$43.9M | −$86.4M | $14.5M | −$4.6M | −$56.8M | −$52.5M | −$34.7M | −$25.3M | −$15.4M |
| Net income | −$130.3M | −$77.4M | −$219.7M | $35.4M | −$25.7M | −$68.9M | −$55.4M | −$36.2M | −$25.2M | −$12.9M |
| Basic EPSper diluted share | -$5.02 | -$4.48 | -$49.76 | $0.24 | -$0.22 | -$0.68 | -$1.22 | -$3.89 | -$15.13 | -$7.84 |
| Diluted EPSper diluted share | -$5.02 | -$4.49 | -$49.76 | $0.10 | -$0.22 | -$0.68 | -$1.22 | -$3.89 | -$15.13 | -$7.84 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 6, 2026Form 4 | Brunn CarstenPresident and CEO | SellCommon Stock | 23.8K | $6.82 | $162.1K | 323.5K |
| Jan 6, 2026Form 4 | Miljkovic MilosChief Medical Officer | SellCommon Stock | 3.6K | $6.82 | $24.4K | 58.8K |
| Jan 6, 2026Form 4 | Davis BlaineChief Financial Officer | SellCommon Stock | 10.6K | $6.82 | $72.2K | 121.2K |
| Dec 4, 2025Form 4 | BARABE TIMOTHY CDirector | BuyCommon Stock | 30.0K | $6.86 | $205.8K | 54.4K |
| Apr 11, 2025Form 4 | SPRINGER TIMOTHY ADirector,TenPercentOwner | BuyCommon Stock · indirect | 36.3K | $10.77 | $391.4K | 656.5K |